Responsiveness and construct validity of EPIC-26, AQoL-6D and SF-6D following treatment in prostate cancer [PDF]
BMC Cancer, 2023 Purpose To assess construct validity and responsiveness of the Expanded Prostate Cancer Index Composite Instrument (EPIC-26) relative to the Short-Form Six-Dimension (SF-6D) and Assessment of Quality of Life 6-Dimension (AQoL-6D) in patients following ...
Norma B. Bulamu +3 more
doaj +3 more sources
Obtaining SF-6D utilities from FACT-H&N in thyroid carcinoma patients: development and results from a mapping study [PDF]
Frontiers in Endocrinology, 2023 ObjectiveThere is limited evidence for mapping clinical tools to preference-based generic tools in the Chinese thyroid cancer patient population. The current study aims to map the FACT-H&N (Functional Assessment of Cancer Therapy-Head and Neck Cancer)
Qing Yang +4 more
doaj +3 more sources
Prediction of the SF-6D utility score from Lung cancer FACT-L: a mapping study in China [PDF]
Health and Quality of Life Outcomes, 2023 Objective To develop a mapping algorithm for generating the Short Form Six-Dimension (SF-6D) utility score based on the Functional Assessment of Cancer Therapy-Lung (FACT-L) of lung cancer patients.
Qing Yang +3 more
doaj +3 more sources
Psychometric performance of the CFQ-R-8D compared to the EQ-5D-3L and SF-6D in people with cystic fibrosis [PDF]
Journal of Patient-Reported OutcomesObjective This study aimed to compare the psychometric performance of the Cystic Fibrosis Questionnaire–Revised–8 Dimensions (CFQ-R-8D), a new, condition-specific, preference-based measure, with that of generic preference-based measures EQ-5D-3L and ...
Clara Mukuria +6 more
doaj +3 more sources
Mapping the EORTC QLQ-C30 and QLQ-LC13 to the SF-6D utility index in patients with lung cancer using machine learning and traditional regression methods [PDF]
Health and Quality of Life OutcomesBackground Preference-based measures of health-related quality of life (HRQoL), such as the Short Form Six-Dimension (SF-6D) is essential for health economic evaluations.
Longlin Jiang +12 more
doaj +3 more sources
Predictors of health state utility values using SF-6D for Chinese adult patients with β-thalassemia major [PDF]
Frontiers in Public Health, 2023 BackgroundPatients with β-thalassemia major (β-TM), predominantly adult patients, are associated with physical, mental, and social problems, that result in decreased quality of life (QoL).
Runqi Zhang +14 more
doaj +3 more sources
Validity and responsiveness of EQ-5D-5L and SF-6D in patients with health complaints attributed to their amalgam fillings: a prospective cohort study of patients undergoing amalgam removal [PDF]
Health and Quality of Life Outcomes, 2021 Background Evidence of health utility changes in patients who suffer from longstanding health complaints attributed to dental amalgam fillings are limited.
Admassu N. Lamu +5 more
doaj +3 more sources
A head-to-head comparison of EQ-5D-5 L and SF-6D in Chinese patients with low back pain [PDF]
Health and Quality of Life Outcomes, 2019 Background The comparative performance of the 3-level EuroQol 5-dimension and Short Form 6-dimension (SF-6D) has been investigated in patients with low back pain (LBP).
Ziping Ye, Lihua Sun, Qi Wang
doaj +3 more sources
A comparative study of Chinese medicine quality of life assessment scale (CQ-11D) and EQ-5D-5L and SF-6D scales based on Chinese population. [PDF]
Qual Life Res, 2023 To measure health-related quality of life in the Chinese population using three universal health utility scales (CQ-11D, EQ-5D-5L, and SF-6D) and to compare the differences in the results obtained by the different scales to provide a reference for future
Zhou J +7 more
europepmc +2 more sources
QALYs and rare diseases: exploring the responsiveness of SF-6D, EQ-5D-5L and AQoL-8D following genomic testing for childhood and adult-onset rare genetic conditions in Australia. [PDF]
Health Qual Life Outcomes, 2023 While a growing body of literature has examined the validity of generic and disease-specific patient-reported outcome measures (PROMs) in rare conditions and discussed the challenges of using PROMs in the context of genomic medicine, there is limited ...
Pan T, Wu Y, Buchanan J, Goranitis I.
europepmc +2 more sources